ATE445402T1 - Neue verwendung von pde5-hemmern - Google Patents

Neue verwendung von pde5-hemmern

Info

Publication number
ATE445402T1
ATE445402T1 AT05716901T AT05716901T ATE445402T1 AT E445402 T1 ATE445402 T1 AT E445402T1 AT 05716901 T AT05716901 T AT 05716901T AT 05716901 T AT05716901 T AT 05716901T AT E445402 T1 ATE445402 T1 AT E445402T1
Authority
AT
Austria
Prior art keywords
pde5 inhibitors
new use
pde5
inhibitors
new
Prior art date
Application number
AT05716901T
Other languages
English (en)
Inventor
Torsten Dunkern
Christian Schudt
Friedrich Grimminger
Ardeschir Ghofrani
Manfred Kaps
Bernhard Rosengarten
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of ATE445402T1 publication Critical patent/ATE445402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05716901T 2004-03-05 2005-03-03 Neue verwendung von pde5-hemmern ATE445402T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04100909 2004-03-05
PCT/EP2005/050958 WO2005089766A1 (en) 2004-03-05 2005-03-03 Novel use for pde5 inhibitors

Publications (1)

Publication Number Publication Date
ATE445402T1 true ATE445402T1 (de) 2009-10-15

Family

ID=34928893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716901T ATE445402T1 (de) 2004-03-05 2005-03-03 Neue verwendung von pde5-hemmern

Country Status (9)

Country Link
US (2) US7666872B2 (de)
EP (1) EP1740183B8 (de)
JP (1) JP4838792B2 (de)
AT (1) ATE445402T1 (de)
AU (1) AU2005224043B2 (de)
CA (1) CA2557792C (de)
DE (1) DE602005017135D1 (de)
ES (1) ES2334682T3 (de)
WO (1) WO2005089766A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841300B2 (en) * 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
EP2079739A2 (de) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-onderivate als kalziumrezeptorantagonisten
JP2010527928A (ja) * 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
AU2012201640B2 (en) * 2007-06-13 2014-09-04 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
DK2282779T3 (da) * 2008-04-29 2013-05-27 Pharnext Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
MX2011002060A (es) 2008-08-25 2011-04-05 Irm Llc Moduladores de la senda de hedgehog.
US8273849B2 (en) * 2009-12-30 2012-09-25 Sabic Innovative Plastics Ip B.V. Isosorbide-based polycarbonates, method of making, and articles formed therefrom
US8888802B2 (en) * 2010-12-21 2014-11-18 Alcon Research, Ltd. Vitrectomy probe with adjustable cutter port size
EP2535049A1 (de) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil zur Behandlung von Demenz
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
RU2497203C2 (ru) * 2012-02-13 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы силденафилом, в том числе при l-name-индуцированном дефиците оксида азота
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
US10647791B2 (en) 2018-03-30 2020-05-12 Sekisui Chemical Co., Ltd. Polyvinyl alcohol used as dispersing agents for polyvinyl chloride suspension polymerization, dispersing agents comprising the polyvinyl alcohol, and method for producing polyvinyl chloride using the polyvinyl alcohol
US20250041309A1 (en) * 2021-12-14 2025-02-06 Zhenao Jinyinhua Pharmaceutical Use of aildenafil or salt thereof in preparation of medicine for preventing or treating ischemic brain damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026940A1 (en) 1995-03-01 1996-09-06 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
KR20000010919A (ko) * 1996-05-31 2000-02-25 모치다 에이 Cgmp­pde 저해작용이 있는 피리도카르바졸 유도체
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JPH10298164A (ja) * 1997-02-27 1998-11-10 Tanabe Seiyaku Co Ltd イソキノリノン誘導体、その製法及びその合成中間体
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
PL363679A1 (en) * 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
WO2003051346A2 (en) 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure

Also Published As

Publication number Publication date
EP1740183A1 (de) 2007-01-10
US8278300B2 (en) 2012-10-02
JP2007526285A (ja) 2007-09-13
US7666872B2 (en) 2010-02-23
JP4838792B2 (ja) 2011-12-14
US20070185114A1 (en) 2007-08-09
AU2005224043B2 (en) 2010-06-24
CA2557792A1 (en) 2005-09-29
DE602005017135D1 (de) 2009-11-26
EP1740183B8 (de) 2009-11-25
EP1740183B1 (de) 2009-10-14
CA2557792C (en) 2012-12-18
WO2005089766A1 (en) 2005-09-29
US20100179152A1 (en) 2010-07-15
AU2005224043A1 (en) 2005-09-29
ES2334682T3 (es) 2010-03-15

Similar Documents

Publication Publication Date Title
ATE445402T1 (de) Neue verwendung von pde5-hemmern
NO20071127L (no) Triazoloftalaziner
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
EA200870409A1 (ru) Антагонисты киназы pi3
ATE461217T1 (de) Glp-1-verbindungen
NO20081636L (no) FAP - inhibitorer
ATE400567T1 (de) Kinaseinhibitoren
EP2060040A4 (de) Verwendung von satztokens in transaktionen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
DE602005017302D1 (de) Synchronisierung von parametrischer raumtonkodierung mit extern bereitgestelltem downmix
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
EA200700702A1 (ru) Аналоги локсапина и способы их применения
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
UY28344A1 (es) Nuevos compuestos
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE50309381D1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
ATE466819T1 (de) Verwendung von nitratsalzen zur unterdrückung störender gerüche
DE602004011946D1 (de) Alkalisalze von protonenpumpen-hemmern
CY1111328T1 (el) Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα
DE602006020585D1 (de) Neue cysteinproteasehemmer und ihre therapeutische anwendung
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
ATE461189T1 (de) Neue 6-pyridylphenanthridine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties